Form 8-K - Current report:
SEC Accession No. 0000950170-25-063987
Filing Date
2025-05-06
Accepted
2025-05-06 08:19:30
Documents
13
Period of Report
2025-05-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cogt-20250506.htm   iXBRL 8-K 60835
2 EX-99.1 cogt-ex99_1.htm EX-99.1 97574
3 GRAPHIC img214414700_0.jpg GRAPHIC 236417
  Complete submission text file 0000950170-25-063987.txt   612764

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cogt-20250506.xsd EX-101.SCH 28711
15 EXTRACTED XBRL INSTANCE DOCUMENT cogt-20250506_htm.xml XML 4697
Mailing Address 275 WYMAN STREET 3RD FLOOR WALTHAM MA 02451
Business Address 275 WYMAN STREET 3RD FLOOR WALTHAM MA 02451 617-945-5576
Cogent Biosciences, Inc. (Filer) CIK: 0001622229 (see all company filings)

EIN.: 465308248 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38443 | Film No.: 25915370
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)